Hormonal Treatment Before Radical Prostatectomy: A 3-Year Followup

Aus, Gunnar; Abrahamsson, Per‐Anders; Ahlgren, Göran; Hugosson, Jonas; Lundberg, Susanne; Schain, Moddy; Schelin, Sonny; Pedersen, Katja Venborg

doi:10.1016/s0022-5347(01)63230-0

Cited by 82 publications

(40 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the three other studies that measured bDFS, 16,22,23 findings were similar in that there was no difference in survival rates between treatment groups at 38, 36 and 48 months follow-up.…”

mentioning

confidence: 54%

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Hummel

Paisley²,

Morgan³

et al. 2003

Health Technol Assess

106

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report. HTAISSN 1366-5278 © Queen's Printer and Controller of HMSO 2003This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.Applications for commercial reproduction should be addressed to HMSO,The Copyright Unit, St Clements House, 2-16 Colegate, Norwich, NR3 1BQ.Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

show abstract

“…In the three other studies that measured bDFS, 16,22,23 findings were similar in that there was no difference in survival rates between treatment groups at 38, 36 and 48 months follow-up.…”

mentioning

confidence: 54%

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Hummel

Paisley²,

Morgan³

et al. 2003

Health Technol Assess

106

View full text Add to dashboard Cite

show abstract

“…However, this modality only reduces the number of positive postoperative margins after radical prostatectomy (RP), but without any influence on overall patient survival. 15 The mechanism whereby HT and RT interact has been studied in vivo in animal models.…”

Section: Rationales For Combined Treatment Adt-ebrtmentioning

confidence: 99%

Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art

Milecki¹

2010

CMAR

View full text Add to dashboard Cite

Androgen-deprivation therapy (ADT) is used routinely in combination with definitive external beam radiation therapy (EBRT) in patients with high-risk clinically localized or locally advanced disease. The combined treatment (ADT-EBRT) also seems to play a significant role in improving treatment results in the intermediate-risk group of prostate cancer patients. On the other hand, there is a growing body of evidence that treatment with ADT can be associated with serious and lifelong adverse events including osteoporosis, cardiovascular disease, diabetes, and many others. Almost all ADT adverse events are time dependant and tend to increase in severity with prolongation of hormonal manipulation. Therefore, it is crucial to clearly state the optimal schedule for ADT in combination with EBRT, that maintaining the positive effect on treatment efficacy would keep the adverse events risk at reasonable level. To achieve this goal, treatment schedule may have to be highly individualized on the basis of the patient-specific potential vulnerability to adverse events. In this study, the concise and evidence-based review of current literature concerning the general rationales for combining radiotherapy and hormonal therapy, its mechanism, treatment results, and toxicity profile is presented.

show abstract

“…All the studies initially demonstrated a decrease in positive margin rates; however, the four studies that provided longer follow-up demonstrated no difference in biochemical-free survival. [42][43][44][45][46] Many studies included patients with low-risk disease and possibly could not benefit from a multimodality approach.…”

Section: Neo-adjuvant Systemic Treatmentmentioning

confidence: 99%

Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy

Kibel

Nelson

2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The management of high-risk prostate cancer following radical prostatectomy remains a treatment dilemma. Multimodality approaches incorporating surgery, radiation therapy and systemic agents offer the hope of improved cure rates; however, most randomized studies to date are either immature or negative. The systemic treatment options best studied is androgen deprivation, which has been shown to demonstrate a survival advantage in patients with lymph node-positive disease. Systemic chemotherapy has demonstrated a modest survival advantage in androgen-independent disease. Current studies are exploring its role in the adjuvant and neo-adjuvant setting. Lastly, recent randomized trials have demonstrated a biochemical advantage to adjuvant radiation therapy, but it remains to be seen if this will translate to an improvement is survival end points or if salvage radiation therapy would be just as effective. In this update article, we review the use of external beam radiation therapy and systemic agents in combination with surgery for high-risk prostate cancer patients.

show abstract

Hormonal Treatment Before Radical Prostatectomy: A 3-Year Followup

Cited by 82 publications

References 10 publications

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art

Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy

Contact Info

Product

Resources

About